Aurora Biosciences

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

Retrieved on: 
Wednesday, January 3, 2024
Health, Science, Radiology, Other Science, Oncology, Aurora Biosciences, Multimedia, Knowledge, Vertex Pharmaceuticals, GPCR, Destiny, Cancer, Radiopharmaceutical, Pharmacology, G protein-coupled receptor

Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.

Key Points: 
  • Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.
  • Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
  • He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics.
  • “The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field.”

Molecular Assemblies Appoints Mark Nibbe Vice President of Operations

Retrieved on: 
Tuesday, December 6, 2022
Aurora, Aurora Biosciences, Therapy, UC, Publication, University of California, San Diego, FES, DNA, Synthetic biology, Precision medicine, Reading, Multimedia, Engineering, CRISPR, Arthur Nibbs, Electronics, SAN, Molecular assembler, Management, Fine chemical, Illumina, Operation

SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Mark Nibbe as Vice President, Operations.

Key Points: 
  • SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the appointment of Mark Nibbe as Vice President, Operations.
  • "Mark brings deep technical experience and leadership vision to enable new products and manufacturing capabilities by building the operational ecosystem from validated processes to nimble, collaborative teams," said Michael J. Kamdar, President and CEO of Molecular Assemblies.
  • "We welcome Mark as Molecular Assemblies begins our Key Customer Program and drives our Fully Enzymatic Synthesis technology to commercialization."
  • Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products.

Laronde Appoints John Mendlein as Chief Executive Officer

Retrieved on: 
Thursday, August 4, 2022
Aurora, Multimedia, Johnson & Johnson, CEO, Aurora Biosciences, Senda, Ecosystem, Growth, John Mendlein, Board, Director, Debiopharm, Life, Therapy, Cell, Erna, Twitter, RNA, Drug development, Biology, Omega, Publication, Protein, Flagship Pioneering, LinkedIn, Medicine, Immune system, Vertex Pharmaceuticals, Vaccine, Pharmaceutical industry, Management, Flagship, Giselle Laronde, Moderna

D., the company's Chairman, will become its interim Chief Executive Officer, effective this month.

Key Points: 
  • D., the company's Chairman, will become its interim Chief Executive Officer, effective this month.
  • Mendlein succeeds Diego Miralles, M.D., who joined Laronde as CEO in December 2020 from Vividion Therapeutics, Inc. and Johnson & Johnson in San Diego.
  • "I look forward to my continuing role engaging with Flagship as an Advisor and am grateful for my time at Laronde and wish John all the best in his new role."
  • John Mendlein is an executive partner at Flagship Pioneering, contributing to Flagship's strategic and operational objectives, including the origination of new Flagship Labs companies.

Healthcare Technology Veteran Greg Nagy Joins MDisrupt as Chief Operating Officer

Retrieved on: 
Wednesday, May 25, 2022
Other Health, Health, Data Management, Technology, Managed Care, Aurora, MBA, Engineering, UC, Biological engineering, Vertex Pharmaceuticals, Leadership, Patient, Pepperdine University, University of California, San Diego, Instinct, Efficiency, Industry, Global marketing, Biotechnology, Bausch Health, Technology, Aurora Biosciences, LinkedIn, Twitter, Amgen, Growth, CEO, Management

MDisrupt , a digital health intelligence company, announced today that Greg Nagy has been appointed as Chief Operating Officer.

Key Points: 
  • MDisrupt , a digital health intelligence company, announced today that Greg Nagy has been appointed as Chief Operating Officer.
  • Mr. Nagy is a veteran global commercial executive in the life sciences and medical technology industries.
  • He previously served as Chief Marketing Officer at Drawbridge Health and Vice President of Global Marketing at Topcon Eyecare.
  • Hiring a full-time chief operating officer is essential as we become a product-led and technology focused company.

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Pharmaceutical, Health, Aurora, Industry, Time, Assistant professor, Cancer, Growth, Vertex Pharmaceuticals, Howard Hughes Medical Institute, HIV/AIDS, Computer science, SAB, Protein, Synthetic biology, Therapy, Senomyx, Structural biology, Multimedia, Molecular biophysics, Dew point, Systems biology, Biochemistry, Harvard University, Senior lecturer, California Institute of Technology, Stanford University, CSO, CEO, Broad Institute, Glaucoma, Aurora Biosciences, NASDAQ, Board, Columbia University Irving Medical Center, Harvard Medical School, Research, Drug discovery, Cystic fibrosis, Relay, Associate, Pharmaceutical industry, Management

Today, Octant , a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member.

Key Points: 
  • Today, Octant , a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member.
  • Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics.
  • Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform.
  • and co-founder and Board Member at Relay Therapeutics (NASDAQ:RLAY) and Board member and founding CSO at Dewpoint Therapeutics.

Tentarix Biotherapeutics Emerges with $50 Million Series A

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, General Health, Medical Devices, Health, Oncology, Aurora, LLP, Versant, Corporate development, Amgen, Protein engineering, Cell, Technology, Solution, Destiny, DRS, Senior, Initial public offering, PricewaterhouseCoopers, IL2R, Regeneron Pharmaceuticals, Therapy, Sanofi, Innovation, Proteomics, Autoimmune disease, Patient, Biology, Terra Venture Partners, Biotechnology, Company, CEO, Aurora Biosciences, NASDAQ, Saṃsāra, Foundation, Pharmacology, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Management, Tentarix, Versant Ventures, Samsara BioCapital, TENTARIX, VERSANT VENTURES, SAMSARA BIOCAPITAL

Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.

Key Points: 
  • Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.
  • This financing allows us to develop multiple programs for oncology and autoimmune disease based on the Tentarix technology platform.
  • The company's proprietary platform facilitates high throughput discovery and optimization of biotherapeutics with high cell selectivity, differentiated functionality, and robust mammalian expression that enables molecular developability.
  • Tentarix is advancing programs in many other fields including cell type specific reprogramming and cell population specific delivery and internalization.